

DOCKET NO. 17224 CON (AP)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of
John Sefton

Serial No: 10/820,298

Filed: April 7, 2004

For: TAZAROTENE AND
CORTICOSTEROID TREATMENT FOR
PSORIASIS

Group Art Unit: 1616

Confirmation No: 7456

Examiner: Badio, Barbara P

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION
OVER A PRIOR PATENT**

Dear Sir:


The owner, Allergan, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 USC 154 and 156 and 173, as presently shortened by any terminal disclaimer, of Patent Application No. 09/367,712. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent is commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 USC 154 to 156 and 173 of the prior patents, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily

disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is an agent of record.

Respectfully submitted,



Brent A. Johnson

Registration No. 51,851

Agent of Record

Telephone: 714/246-4348

Telecopier: 714/246-4249

Date: June 9, 2005

X Please charge the terminal disclaimer fee under 37 CFR 1.20(d) to Account No. 01-0885. A duplicate of this terminal disclaimer is enclosed.

X PTO suggested wording for terminal disclaimer was unchanged.

Please direct all correspondence to:

Brent A. Johnson (T2-7H)
Agent of Record
ALLERGAN, INC.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714/246-4348
Telecopier: 714/246-4249


CERTIFICATE OF FIRST CLASS MAIL UNDER 37 C.F.R. §1.10

I hereby certify that this Terminal Disclaimer and any additional documents enclosed herein are being deposited with the United States Postal Service on June 10, 2005 in an envelope as "First Class Mail Post Office To Addressee" mailing label number with sufficient postage for First Class Mail addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Date: June 10, 2005

Bonnie Ferguson

Name of person mailing paper



Signature of person mailing paper